Runnymede Capital Advisors Inc. bought a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the fourth quarter, Holdings Channel.com reports. The firm bought 1,782 shares of the exchange traded fund’s stock, valued at approximately $160,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $29,000. Avior Wealth Management LLC boosted its position in SPDR S&P Biotech ETF by 393.6% in the fourth quarter. Avior Wealth Management LLC now owns 385 shares of the exchange traded fund’s stock valued at $35,000 after buying an additional 307 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $38,000. Finally, Bank of Jackson Hole Trust acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $43,000.
SPDR S&P Biotech ETF Price Performance
Shares of SPDR S&P Biotech ETF stock opened at $87.12 on Friday. The company’s 50 day moving average price is $89.59 and its two-hundred day moving average price is $94.38. The firm has a market capitalization of $5.65 billion, a P/E ratio of 11.47 and a beta of 0.99. SPDR S&P Biotech ETF has a fifty-two week low of $81.14 and a fifty-two week high of $105.47.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- How to Profit From Growth Investing
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What is the FTSE 100 index?
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Profitably Trade Stocks at 52-Week Highs
- Micron Stock Will Retest All-Time Highs This Year
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.